T1	Participants 134 153	chronic hepatitis C
T2	Participants 779 858	Interferon alpha monotherapy relapsers with chronic hepatitis C were randomised
T3	Participants 1181 1247	Only patients with negative HCV RNA at week 10 continued treatment
T4	Participants 1308 1452	Thirty-seven patients were enrolled, 19 (6 females, median age 43) in the 24 week and 18 (5 females, median age 40) in the 48 week treatment arm
T5	Participants 1454 1507	Baseline characteristics were similar in both groups.
T6	Participants 2372 2406	relapsers with chronic hepatitis C
